Evidence map›Paper›PMID 25632271›Full record

ArticleJournal of inflammation (London, England)2015

Anti-inflammatory effects of adenosine N1-oxide.

Keizo Kohno, Emiko Ohashi, Osamu Sano, Hajime Kusano, Toshio Kunikata, Norie Arai, Toshiharu Hanaya, Toshio Kawata, Tomoyuki Nishimoto, Shigeharu Fukuda

Open access · goldAbstract read
In one paragraph

Article in Journal of inflammation (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Protective Effect ofFood science & nutrition · 2026
    Article
  2. Immunomodulatory Effects ofInternational journal of molecular sciences · 2026
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Keizo Kohno *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Emiko Ohashi *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Osamu Sano *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Hajime Kusano *Functional Dye Division, Functional Dye Department, Hayashibara Co., Ltd, Okayama, Japan.
Toshio Kunikata *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Norie Arai *Applied Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Toshiharu Hanaya *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Toshio Kawata *Functional Dye Division, Functional Dye Department, Hayashibara Co., Ltd, Okayama, Japan.
Tomoyuki Nishimoto *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Shigeharu Fukuda *Core Technology Division, Research and Development Center, Hayashibara Co., Ltd, Okayama, Japan.
Hayashibara (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdenosine is a potent endogenous anti-inflammatory and immunoregulatory molecule. Despite its promise, adenosine's extremely short half-life in blood limits its clinical application. Here, we examined adenosine N1-oxide (ANO), which is found in royal jelly. ANO is an oxidized product of adenosine at the N1 position of the adenine base moiety. We found that it is refractory to adenosine deaminase-mediated conversion to inosine. We further examined the anti-inflammatory activities of ANO in vitro and in vivo.

methodsThe effect of ANO on pro-inflammatory cytokine secretion was examined in mouse peritoneal macrophages and the human monocytic cell line THP-1, and compared with that of adenosine, synthetic adenosine receptor (AR)-selective agonists and dipotassium glycyrrhizate (GK2). The anti-inflammatory activity of ANO in vivo was examined in an LPS-induced endotoxin shock model in mice.

resultsANO inhibited secretion of inflammatory mediators at much lower concentrations than adenosine and GK2 when used with peritoneal macrophages and THP-1 cells that were stimulated by LPS plus IFN-γ. The potent anti-inflammatory activity of ANO could not be solely accounted for by its refractoriness to adenosine deaminase. ANO was superior to the synthetic A1 AR-selective agonist, 2-chloro-N(6)-cyclopentyladenosine (CCPA), A2A AR-selective agonist, 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamideadenosine hydrochloride (CGS21680), and A3 AR-selective agonist, N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide (IB-MECA), in suppressing the secretion of a broad spectrum of pro-inflammatory cytokines by peritoneal macrophages. The capacities of ANO to inhibit pro-inflammatory cytokine production by THP-1 cells were comparable with those of CCPA and IB-MECA. Reflecting its potent anti-inflammatory effects in vitro, intravenous administration of ANO significantly reduced lethality of LPS-induced endotoxin shock. A significant increase in survival rate was also observed by oral administration of ANO. Mechanistic analysis suggested that the up-regulation of the anti-inflammatory transcription factor c-Fos was, at least in part, involved in the ANO-induced suppression of pro-inflammatory cytokine secretion.

conclusionsOur data suggest that ANO, a naturally occurring molecule that is structurally close to adenosine but is functionally more potent, presents potential strategies for the treatment of inflammatory disorders.

Indexed as

AdenosineAdenosine receptor agonistsAnti-inflammatory effectEndotoxin shockPro-inflammatory cytokines

Identifiers

PMID25632271
PMCPMC4308844
OpenAlexW2097945733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.